Interferon-β1a does not reduce expression of CCR5 and CXCR3 on circulating T cells

Journal of Neuroimmunology

Volumn 141, Issue 1-2, 2003, Pages 150-154

  Kivisäkk, Pia ^a   Cotleur, Anne C ^a   Lee, Jar Chi ^a   Rudick, Richard A ^a   Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CCR5; CXCR3; Interferon 1a

Indexed keywords

BETA1A INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3;

ARTICLE; BLOOD ANALYSIS; CELL DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; HUMAN; HUMAN CELL; INJECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

EID: 18844482559     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00247-9     Document Type: Article

References (17)

1. Balashov K.E., Rottman J.B., Weiner H.L., Hancock W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6873-6878.
2. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 343:2000;898-904.
3. Kivisäkk P., Trebst C., Liu Z., Tucky B.H., Sørensen T.L., Rudick R.A., Mack M., Ransohoff R.M. T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin. Exp. Immunol. 129:2002;510-518.
4. Kivisäkk P., Liu Z., Trebst C., Tucky B.H., Wu L., Stine J., Mack M., Rudick R.A., Campbell J.J., Ransohoff R.M. Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes. Methods. 29:2003;319-325.
5. Kivisäkk P., Trebst C., Lee J.-C., Tucky B.H., Rudick R.A., Campbell J.J., Ransohoff R.M. Expression of CCR2, CCR5 and CXCR3 by CD4+ T-cells is stable during a two-year longitudinal study but varies widely between individuals. J. Neurovirol. 9:2003;291-299.
6. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:2003;15-23.
7. Moser B., Loetscher P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2:2001;123-128.
8. Rudick R.A., Cookfair D.L., Simonian N.A., Ransohoff R.M., Richert J.R., Jacobs L.D., Herndon R.M., Salazar A.M., Fischer J.S., Granger C.V., Goodkin D.E., Simon J.H., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munchsauer F.E., O'Reilly K., Priore R.L., Whitham R.H. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. J. Neuroimmunol. 93:1999;8-14.
9. Simon J.H., Jacobs L.D., Campion M., Wende K., Simonian N., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Alam J.J., Fischer J.S., Goodkin D.E., Granger C.V., Lajaunie M., Martens-Davidson A.L., Meyer M., Sheeder J., Choi K., Scherzinger A.L., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Whitham R.H. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann. Neurol. 43:1998;79-87.
10. Simpson J.E., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 84:1998;238-249.
11. Sørensen T.L., Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology. 57:2001;1371-1376.
12. Sørensen T.L., Sellebjerg F. Selective suppression of chemokine receptor CXCR3 expression by interferon-beta1a in multiple sclerosis. Mult. Scler. 8:2002;104-107.
13. Sørensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., Ransohoff R.M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:1999;807-815.
14. Teleshova N., Pashenkov M., Huang Y.M., Söderström M., Kivisäkk P., Kostulas V., Haglund M., Link H. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J. Neurol. 249:2002;723-729.
15. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
16. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 56:2001;1628-1636.
17. Zang Y.C., Halder J.B., Samanta A.K., Hong J., Rivera V.M., Zhang J.Z. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J. Neuroimmunol. 112:2001;174-180.